Spyre Therapeutics, Inc. SYRE Available-for-Sale Debt Securities - Amortized Cost
Available-for-Sale Debt Securities - Amortized Cost at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s available-for-sale debt securities - amortized cost.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s available-for-sale debt securities - amortized cost?
- Spyre Therapeutics, Inc. (SYRE) reported available-for-sale debt securities - amortized cost of $645.05M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s available-for-sale debt securities - amortized cost changed year-over-year?
- Spyre Therapeutics, Inc.'s available-for-sale debt securities - amortized cost increased by 25.1% year-over-year, from $515.68M to $645.05M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s available-for-sale debt securities - amortized cost?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s available-for-sale debt securities - amortized cost has grown at a 217.8% compound annual growth rate (CAGR), from $20.88M to $669.94M.
- What does available-for-sale debt securities - amortized cost mean?
- This is the cost basis of debt securities classified as available-for-sale, adjusted for amortization of premiums or discounts. It represents the value of the investment portfolio before accounting for current market price fluctuations. This provides a baseline for evaluating the performance of the company's liquid investment strategy.